BioSpace News Archive

Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced Janssen Biotech, Inc. (Janssen) received U.S. Food and Drug Administration (FDA) approval of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in combination with Kyprolis® (carfilzomib) and dexamethasone (Kd) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy.

Qualigen Therapeutics, Inc. (Nasdaq: QLGN) today announced the closing of its previously announced registered direct offering with certain institutional investors for the purchase and sale of 5,880,000 shares of common stock for $1.50 per share (i.e., for aggregate gross proceeds of $8,820,000).

Researchers at the Nagourney Cancer Institute and Metabolomycs, Inc. announced in issue of PLOS ONE a study that showed that COVID-19 related illness severity and death can be predicted by a blood test that is conducted at the time of diagnosis.

An orphan drug is a pharmaceutical product which is utilized in the diagnosis, prevention, and treatment of rare and serious diseases.

Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of medicines, announced that Douglas E. Williams, Ph.D., President and CEO, will participate in a virtual fireside chat at the 4th Annual Evercore ISI HealthCONx Conference.

Inhibrx, Inc today announced that the U.S. Food and Drug Administration, or FDA, has granted orphan-drug designation for INBRX-109 for the treatment of chondrosarcoma.

Cybin to Present at the Stifel GMP 2 nd Annual Future of Healthcare Conference on December 8, 2021.

Nanomix Corporation today announced the Company has resubmitted an Emergency Use Authorization (EUA) application to the U.S. Food and Drug Administration (FDA) for its eLab COVID-19 rapid antigen test.

Akebia Therapeutics, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 21 newly-hired employees options to purchase an aggregate of 85,000 shares of Akebia’s common stock on November 30, 2021, as inducements material to each such employee’s entering into employment with Akebia.

Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), today confirmed that the Company’s RT-PCR test for SARS-CoV-2, the virus that causes COVID-19, can successfully detect the recently emerged Omicron variant of the virus.